MetaCap

Evolent Health Inc Class A (EVH)

NYSE: EVHConsumer DiscretionaryOther Consumer ServicesUSD

3.90+0.47 (+13.70%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

EVH stock chart

Technical analysis

Key statistics

All statistics
Market cap
$441.11M
EPS (TTM)
-$4.46
52-week range
2.10 – 6.26
Day range
3.45 – 4.16
Volume / Avg
4.42M / 2.16M
Beta
—

52-week range

$2.10$6.26

EVH stock today

Shares of Evolent Health (EVH) finished higher on Nov 20 at $3.90, a gain of 13.70% or $0.47 per share, versus the S&P 500's 3.70% decline. Volume was 2.0x the average at 4.42M shares, a sign of unusually heavy trading. Shares are 37.6% below their 52-week high of $6.26, set on Jul 14, 2026 and 86.2% above the 52-week low of $2.10, in the middle of the past year's range.

EVH is down 2.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 5.8%. Evolent Health has posted a net loss over the last twelve months (EPS of -$4.46), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Evolent Health

Company profile

Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company offers integrated value-based care platform for health plan administration and management. It also provides administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.

Industry
Other Consumer Services
CEO
Mr. Seth Barrie Blackley
Headquarters
Arlington, VA
Employees
4,200
IPO year
2015

Financial highlights

Full financials

In fiscal 2025, Evolent Health generated $1.88 billion in revenue, down 26.6% from fiscal 2024, its first annual decline since 2021. Evolent Health reported a net loss of $534.5 million, compared with a loss of $61.6 million a year earlier. Gross margin was 21.3% (up from 14.4%) and operating margin -21.9%.

Evolent Health annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$1.88B$2.55B$1.96B$1.35B$907.96M
Growth-26.56%+30.09%+45.26%+48.91%-1.80%
Net income$-534.51M$-61.62M$-113.04M$-19.16M$-37.60M
EPS (diluted)$-5.07$-0.81$-1.28$-0.20$-0.44

Analyst forecast

Forecast

Consensus (14 analysts)

buy

Avg. price target

$6.00+53.85%

  • Strong buy 4
  • Buy 8
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $3.00High $8.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.21 vs $-0.05
Surprise
-320.00%

EVH news

All EVH news

Evolent Health peers

Consumer Discretionary sector
EVH peer companies
CompanyPrice% ChgMarket capCompare
BLWBlackrock Limited Duration Income Trust11.07-1.16%$432.83Mvs EVH
CSVCarriage Services Inc.29.03-1.59%$461.06Mvs EVH
GOTUGaotu Techedu Inc. ADR2.06-9.65%$484.21Mvs EVH
LINCLincoln Educational Services Corporation20.12-7.71%$619.32Mvs EVH
EVIEVI Industries Inc.19.78-5.40%$256.57Mvs EVH
PXEDPhoenix Education Partners Inc.19.66-4.19%$721.06Mvs EVH
APEIAmerican Public Education Inc.39.77-2.62%$723.94Mvs EVH
FCFranklin Covey Company13.19+0.61%$149.51Mvs EVH

Indexes, lists and sector

Evolent Health stock FAQ

What is Evolent Health's stock price today?

EVH last traded at $3.90 as of Nov 20, 4:00 PM EST, up 13.70% on the day. Prices are delayed at least 15 minutes.

Who is Evolent Health's CEO?

Mr. Seth Barrie Blackley is the chief executive officer of Evolent Health Inc Class A, which has about 4,200 employees.

What is the EVH 52-week high?

The 52-week high for EVH is $6.26 and the 52-week low is $2.10. The stock is currently 37.6% below its high.

Compare EVH